🇺🇸 FDA
Patent

US 11479602

Methods of treating C5-associated diseases comprising administering anti-C5 antibodies

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 11479602 (Methods of treating C5-associated diseases comprising administering anti-C5 antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K39/3955, A61K45/06